Specialties

Theranostics

Cancer is personal. Its treatment should be too. GE Healthcare’s complete portfolio of Theranostics-enabling solutions is designed specifically for this new era in cancer care. Join us on this journey to transform the approach to cancer discovery, diagnosis, and treatment. Because the future of medicine is here—and it’s personal. Are you ready?

The future of healthcare is Theranostics

We are miraculously diverse. Singular in biology. Unique in variance. United in hope … for a better tomorrow.

DISCOVERY

GE Healthcare’s PET Radiopharmacy drives innovation

Partnering with leading clinical, academic, pharmaceutical, and research organizations to innovate, streamline production and distribution, and commercialize new radiopharmaceuticals and solutions.

DIAGNOSIS

GE is pioneering the solutions that enable unparalleled sensitivity and diagnostic confidence.

Our dedicated portfolio of Theranostics-focused diagnostic imaging solutions was engineered specifically to meet clinicians’ needs—and those of their patients— today and in the future.

THERAPY IMAGING AND MONITORING

Cancer is personal.
Its treatment should be too.

GE Healthcare is shaping the future of Theranostics today with precise imaging and monitoring solutions and innovations of treatment response.

DIGITAL AI

Digital Accuracy for Precision Health

Bringing you leading-edge applications for visualization, quantitation, and dosimetry.

DIGITAL AI PRODUCTS

There is so much data available across molecular imaging today. There are so many connection opportunities and loops to close. GE can help.

Our vision is to connect the teams, data, and decisions in every step—from discovery to diagnosis to treatment — as the only partner with innovations that will ultimately help you deliver intelligently efficient, precise, personalized care.

Practical considerations needed in establishing a Theranostics program from SNMMI 2022: We really have a long way to go to meet the need of the market right now let alone what is coming in the future.

THOUGHT LEADERSHIP

Here's what today’s medical leaders are saying

INNOVATIONS

Only GE Healthcare —for wherever you are on your Theranostics journey

The future is happening now. One-size-fits-all just doesn’t work anymore. At GE Healthcare, we’re personalizing the path to precision healthcare. Join us, as we work toward enabling better outcomes. Join us, as we provide hope.

Researchers and Academic Centers

By partnering with GE Healthcare—the only vendor with a complete Theranostics package—you get ground-breaking technology and the exceptional MI solutions. And, you get the promise of continued research, keeping you at the forefront of your industry.

Community Hospitals and Imaging Centers

You can see the future of molecular imaging—bringing hope to your cancer patients. With GE Healthcare as your partner, you will protect your investments, distinguish your facility from others—and keep your patients close to home.

Referring Physicians

Extending lives and relieving pain is everything. GE Healthcare’s comprehensive approach to Theranostics is the key to disease management. Our approach is part of the future of cancer evaluation and monitoring. And the future is happening now.

Patients

We’re with you on your cancer care journey. We know every step is critical. Every step is hard. That’s why with GE Healthcare you get precise, personal solutions. It’s the future of cancer treatment. And it’s happening now.

Omni Legend 32cm as compared to Discovery MI 25cm. Measurements follow NEMA NU 2-2018.
Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
Source: MEDRaysintell2021
Omni Legend compared to Discovery MI. As demonstrated in phantom testing.
Q.Thera AI is 510(k) pending at the US FDA. Not cleared for sales in the United States.
Compared to using Xeleris’s Dosimetry Toolkit with dose calculations done with external software. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflowfrom data loading to image processing and dose calculation. Results may vary.
Compared to using Xeleris 4 DR Q.Volumetrix MI with manual or external software dose calculation. As demonstrated in an evaluation at 2 sites consisting of 15 SPECT-CT cases and 2 physicians, where each case was processed by 1 of the 2 physicians. Results may vary.
Compared to using Xeleris 4 DR Q.Volumetrix with manual or external software dose calculation. As demonstrated in bench test using 5 SPECT-CT cases. The bench test covered the workflow from data loading to dose calculation using user pre-defined formulas. Results may vary.
https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html#:~:text=Other%20than%20skin%20cancer%2C%20prostate,34%2C500%20deaths%20from%20prostate%20cancer